<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02888106</url>
  </required_header>
  <id_info>
    <org_study_id>MYR 203</org_study_id>
    <nct_id>NCT02888106</nct_id>
  </id_info>
  <brief_title>Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent</brief_title>
  <official_title>A Multicenter, Open-label, Randomised, Comparative, Parallel-Arm, Phase II Study to Assess Efficacy and Safety of Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hepatera Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hepatera Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomised, Comparative, Parallel-Arm Study to Assess Efficacy and Safety of Myrcludex B in
      Combination with Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients with
      Chronic Viral Hepatitis B with Delta-agent
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, randomised, comparative, active-controlled parallel-arm
      phase II study.

      The study will be conducted in Russia. The aim of this study is to investigate efficacy and
      safety of Myrcludex B alone and in combination with peginterferon alfa-2a compared to
      peginterferon alfa-2a alone in patients with chronic viral hepatitis B with delta-agent. The
      study is also aimed at investigating immunogenicity of Myrcludex B and the drug
      pharmacokinetics when used in combination with PEG IFN alfa-2a.

      It is planned to screen 100 patients, and 60 patients will be randomised into four treatment
      arms in the 1:1:1:1 ratio.

        -  Arm A (n=15): PEG IFN alfa-2a 180 µg for 48 weeks

        -  Arm B (n=15): Myrcludex B 2 mg + PEG IFN alfa-2a 180 µg for 48 weeks

        -  Arm C (n=15): Myrcludex B 5 mg + PEG IFN alfa-2a 180 µg for 48 weeks

        -  Arm D (n=15): Myrcludex B 2 mg for 48 weeks
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, Open-label, Randomized, Comparative, parallel-arm phase II study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with negative HDV RNA by PCR</measure>
    <time_frame>72 weeks</time_frame>
    <description>Negativation of HDV RNA by PCR (undetectable HDV RNA) at Week 72 (end of follow-up period)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with negative HDV RNA by PCR</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>Proportion of patients with negative HDV RNA by PCR (undetectable HDV RNA) at Weeks 24 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with normalized ALT</measure>
    <time_frame>24, 48 and 72 weeks</time_frame>
    <description>Proportion of patients with normalized ALT at Weeks 24, 48 and 72</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with combined response</measure>
    <time_frame>24, 48 and 72 weeks</time_frame>
    <description>Combined response is defined as negative HDV RNA and ALT normalization at Weeks 24, 48, and 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with HВsAg response</measure>
    <time_frame>24, 48 and 72 weeks</time_frame>
    <description>HВsAg response is defined as HBsAg negativation or &gt; 0.5 log10 decline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with HBsAg negativation</measure>
    <time_frame>24, 48 and 72 weeks</time_frame>
    <description>undetectable HВsAg with appearance of HbsAg antibodies or without it</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with negative HBV DNA by PCR</measure>
    <time_frame>24, 48 and 72 weeks</time_frame>
    <description>undetectable HBV DNA by PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The severity of fibrosis evaluated by transient elastometry of the liver</measure>
    <time_frame>48 and 72 weeks</time_frame>
    <description>the results of fibroelastometry</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Chronic Viral Hepatitis B With Delta-agent</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PEG IFN alfa-2a 180 µg for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Myrcludex B 2 mg + PEG IFN alfa-2a 180 µg for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Myrcludex B 5 mg + PEG IFN alfa-2a 180 µg for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Myrcludex B 2 mg for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Myrcludex B 10 mg (10 mg once a day) + PEG-IFN alfa-2a 180 μg during 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Myrcludex B 10 mg (5 mg twice a day) + Tenofovir during 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Myrcludex B</intervention_name>
    <description>5 mg (once a day), 5 mg (twice a day), 10 mg (once a day)</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_label>Arm F</arm_group_label>
    <other_name>Bulevirtide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG IFN alfa-2a</intervention_name>
    <description>180 μg (once a week)</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm E</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
    <description>300 mg, orally, once daily</description>
    <arm_group_label>Arm F</arm_group_label>
    <other_name>Viread</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent form.

          2. Males and females 18 to 65 years of age (inclusively).

          3. Patients with chronic hepatitis B (HBeAg-positive or negative) and HBsAg-positive for
             at least 6 months prior to Screening.

          4. Positive for anti-HDV antibodies for at least 6 months prior to Screening.

          5. HDV RNA-positive at Screening.

          6. ALT ≥ 1 x ULN and &lt; 10 x ULN.

          7. The patient agree to use adequate method of contraception during the study, starting
             from the time of Informed Consent signing and until completion of Follow-up Period.

        Exclusion Criteria:

          1. Intolerance or hypersensitivity to the active ingredient or other components of the
             study drug Myrcludex B.

          2. Intolerance or hypersensitivity to interferons alfa, genetically engineered E.coli
             medications, polyethylene glycol or other components of peginterferon alfa-2a.

          3. Previous treatment with Myrcludex B (patients with previous exposure to interferon are
             eligible).

          4. Therapy with antiviral drugs for chronic viral hepatitis B with delta-agent over the
             previous 6 months.

          5. Therapy with anti-tumour agents (including radiotherapy) or immunomodulatory
             medications (including systemic glucocorticoids) over the previous 6 months.

          6. The following laboratory test results at Screening:

               1. Hemoglobin &lt; 100 g/L

               2. Leucocytes &lt; 3000/µL

               3. Neutrophils &lt; 1500/µL

               4. Platelets &lt; 90000/µL

               5. Serum creatinine &gt;1.5 x ULN.

          7. Total bilirubin &gt; 34.2 µM/L. Patients with higher total bilirubin may be enrolled upon
             consultation with the study Medical Monitor, if there is clear evidence that the
             elevated bilirubin is caused by Gilbert's syndrome.

          8. Current or previous decompensated liver disease, including coagulopathy,
             hyperbilirubinemia, hepatic encephalopathy, hypoalbuminaemia, ascites, and oesophageal
             varices haemorrhage; Child-Pugh score of B/C or ≥6 points.

          9. HCV or HIV coinfection (patients with anti-HCV antibodies and no HCV RNA at Screening
             are eligible).

         10. Hepatocellular carcinoma.

         11. Signs of drug- or alcohol-induced liver disease or any other medical conditions
             associated with chronic liver disease (e.g. autoimmune hepatitis, hemochromatosis,
             thalassaemia, alcoholic hepatitis, toxic liver disease).

         12. Contraindications for liver biopsy.

         13. Concurrent malignancy (current diagnosed or suspected malignancy; risk of a previous
             malignancy recurrence).

         14. Severe decompensated cardiovascular diseases, including unstable and poorly controlled
             conditions, over 6 months before Screening.

         15. History of poorly controlled thyroid conditions or clinically significant signs of
             thyroid dysfunction at Screening.

         16. Previous or current severe renal failure or significant renal dysfunction at
             Screening.

         17. Previous or current chronic pulmonary disease with respiratory distortion at
             Screening.

         18. Previous or current severe retinopathy, significant ophthalmology disorders associated
             with diabetes mellitus or hypertension.

         19. Previous or current severe psychiatric disorders at Screening (e.g. severe
             depressions, suicidal attempts, severe neuroses or cognitive disorders).

         20. Previous or current endocrine disorders (hypoglycaemia, hyperglycaemia, diabetes
             mellitus) that are not adequately controlled at Screening.

         21. History of visceral organ transplantation.

         22. Signs of drug and/or alcohol dependence (80 g of alcohol/day for men and 40 g of
             alcohol/day for women) within 1 year before Screening.

         23. History of immune disorders (e.g. idiopathic thrombocytopenic purpura, lupus
             erythematosus, sclerodermia, severe psoriasis, rheumatoid arthritis).

         24. Need for concomitant use of glucocorticoids or myelotoxic agents.

         25. Participation in another clinical study within 30 days prior to enrollment into this
             study.

         26. Pregnant or breast-feeding females.

         27. Any other condition that, in the opinion of Investigator, precludes the patient from
             taking part in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pavel Bogomolov, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yana Delovery, MD</last_name>
    <email>deloveri@ammaxwell.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexander Alexandrov, PhD</last_name>
    <email>alexandrov@ammaxwell.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>State Budgetary educational institution of higher professional education &quot;South Ural State Medical University&quot; Ministry of healthcare</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of healthcare &quot;Specialized Clinical Infectious Diseases Hospital&quot; Ministry of Health</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moscow Regional Research and Clinical Institute</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Bogomolov, PhD</last_name>
      <phone>+7(495) 281-55-85</phone>
      <email>p.bogomolov@monikiweb.ru</email>
    </contact>
    <investigator>
      <last_name>Pavel Bogomolov, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Federal Budget Institution of Science &quot;Central Research Institute of Epidemiology&quot; of The Federal Service on Customers' Rights Protection and Human Well-being Surveillance</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Chulanov</last_name>
      <email>vladimir.chulanov@pcr.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LLC &quot;Clinic of Modern Medicine&quot;</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatyana Stepanova, MD</last_name>
      <email>tvstepa@list.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Company &quot;Gepatolog&quot; LLC</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vyacheslav Morozov</last_name>
      <email>viacheslavmorozov@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of healthcare 'Stavropol regional clinical hospital'</name>
      <address>
        <city>Stavropol'</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2016</study_first_submitted>
  <study_first_submitted_qc>August 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2016</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

